X0206 3 2024-04-19 0 0001661181 Organogenesis Holdings Inc. ORGO 0002020983 Cavorsi Robert C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 0 1 0 0 Vice President, Strategy Class A Common Stock 23579 D Class A Common Stock 739 D Class A Common Stock 215 D Class A Common Stock 2163 D Class A Common Stock 4203 D Class A Common Stock 51750 D Class A Common Stock 57434 D Stock Option (Right to Buy) 15.63 2031-03-09 Class A Common Stock 6519 D Stock Option (Right to Buy) 14.45 2031-07-16 Class A Common Stock 32559 D Stock Option (Right to Buy) 8.03 2032-03-01 Class A Common Stock 19935 D Stock Option (Right to Buy) 2.51 2033-03-15 Class A Common Stock 81000 D Stock Option (Right to Buy) 3.43 2034-02-21 Class A Common Stock 103842 D Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan. The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025. The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025. The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026. The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027. The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028. The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025. The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025. The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026. The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027. The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028. Exhibit 24 Power of Attorney filed herewith. /s/ William R. Kolb, Attorney-in-Fact 2024-04-29